MRGPRX1

Across TCGA pan-cancer cohorts, MRGPRX1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MRGPRX1 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MRGPRX1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MRGPRX1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, LGG, and READ are the cancer types where MRGPRX1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.109	0.931	<.001	18	view →
LGG	OS	Median	All	0.238	0.799	<.001	6	view →
READ	DFS	Median	IV	0.082	0.619	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.731	0.551	.018	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MRGPRX1–ESCA (OS)

Open the ESCA breakdown →